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Abstract
Purpose
To identify the genetic variants associated with breast cancer survival, a genome-wide as-
sociation study (GWAS) was conducted of Korean breast cancer patients.
Methods
From the Seoul Breast Cancer Study (SEBCS), 3,226 patients with breast cancer (1,732 in
the discovery and 1,494 in the replication set) were included in a two-stage GWAS on dis-
ease-free survival (DFS) by tumor subtypes based on hormone receptor (HR) and human
epidermal growth factor receptor 2 (HER2). The associations of the re-classified combined
prognostic markers through recursive partitioning analysis (RPA) of DFS for breast cancer
were assessed with the Cox proportional hazard model. The prognostic predictive values of
the clinical and genetic models were evaluated by Harrell’s C.
Results
In the two-stage GWAS stratified by tumor subtypes, rs166870 and rs10825036 were con-
sistently associated with DFS in the HR+ HER2- and HR- HER2- breast cancer subtypes,
respectively (Prs166870=2.88×10
-7 and Prs10825036=3.54×10
-7 in the combined set). When pa-
tients were classified by the RPA in each subtype, genetic factors contributed significantly
to differentiating the high risk group associated with DFS inbreast cancer, specifically the
HR+ HER2- (Pdiscovery=1.18×10
-8 and Preplication=2.08×10
-5) and HR- HRE2- subtypes
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(Pdiscovery=2.35×10
-4 and Preplication=2.60×10
-2). The inclusion of the SNPs tended to im-
prove the performance of the prognostic models consisting of age, TNM stage and tumor
subtypes based on ER, PR, and HER2 status.
Conclusion
Combined prognostic markers that include clinical and genetic factors by tumor subtypes
could improve the prediction of survival in breast cancer.
Introduction
Breast cancer is one of the most common malignancies among women in the world. Although
breast cancer patients have generally a good prognosis[1], because the 5-year survival for inva-
sive breast cancer cases from 1999 to 2005 was about 90%, large differences exist in survival
rate because of a variety of clinicopathological prognostic factors[2]. The tumor-node-metasta-
sis (TNM) staging system approved by the American Joint Committee on Cancer (AJCC) is a
well-known important prognostic factor[3]. However, there are prognostic differences within
specific stages because of the biological heterogeneity of tumors; thus, additional tumor mark-
ers such as tumor grade, lymphovascular invasion, proliferation markers, estrogen and proges-
terone receptor (ER and PR) status, and human epidermal growth factor receptor 2 (HER2)
overexpression have been suggested to provide a more precise prognosis of breast cancer[3–5].
Among those prognostic factors, ER, PR, and HER2 status have been used for breast tumor
subtypes classification in terms of heterogeneous clinical behavior and systematic therapy rec-
ommendations[6]. The tumor subtype based on ER, PR, and HER2 status has been validated in
independent data set with significant differences in their clinical features even in Asian and Eu-
ropean, early and metastatic breast cancer patients suggesting the robust classification[7–10].
In addition to clinicopathological prognostic factors, there is evidence supporting that in-
herited genetic factors influence the prognosis of breast cancer. Several genome-wide associa-
tion studies (GWAS) have identified common variants associated with the prognosis of breast
cancer at multiple genetic loci including C10orf11, ARRDC3, RAD51L1, PBX1, RoRα, SYT6,
NTN1, OCA2, and ZFHX3 genes[11–15]. Although genetic susceptibility markers influence dif-
ferently the prognosis as well as the risk of breast cancer based on the ER, PR, and/or HER2 sta-
tus[12,15–28], there are no genetic association studies on the prognosis of breast cancer which
consider the heterogeneity of intrinsic tumor subtypes composed of various combinations of
ER, PR, and HER2 status.
In this study, we hypothesized that the association of breast cancer prognosis with common
genetic variants may vary by breast tumor subtypes. This study aims to conduct a two-stage
GWAS for disease-free survival (DFS) in breast cancer stratified by tumor subtypes defined by
the ER, PR, and HER2 status and evaluate the performance of prognostic models that included
genetic variants with well-known clinical factors.
Materials and Methods
Study Population
The Seoul Breast Cancer Study (SEBCS) is a multicenter-based case-control study of female
breast cancer in Seoul, Korea as previously reported[29,30]. This two-stage GWAS included a
total of 3,226 incident breast cancer cases. A total of 4,040 histologically confirmed breast
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cancer patients were recruited from Seoul National University Hospital (SNUH) and ASAN
Medical Center (AMC) between 2001 and 2007. For the discovery stage, 2,273 breast cancer
patients who had been participated in GWAS on breast cancer risk were selected with sufficient
DNA samples and successful genotyping[29]. We excluded subjects who had a previous history
of breast or other cancers before the recruitment (N = 67), were diagnosed with benign breast
disease (N = 17), or had no clinicopathological information (N = 73). After those exclusions
which were not mutually exclusive, the subjects with a metastatic disease (N = 30) on review of
their medical records were additionally excluded and 2,111 subjects remained. For survival
analysis, the subjects who had a follow-up loss or follow-up time of less than 90 days (N = 113)
were excluded and 1,998 subjects (95% of 2,111 eligible subjects) remained. Among those sub-
jects, a total of 1,732 incident breast cancer patients with known tumor subtypes were included
in the discovery set in this study.
For the replication set, a total of 1,837 breast cancer patients were included comprised of 508
SEBCS participants who were not included in the discovery set and 1,329 newly recruited partici-
pants who were histologically confirmed as having breast cancer at SNUH between 2000 and
2008. Of those patients, 1,735 breast cancer patients whose DNA samples were sufficient in con-
centration and purity were successfully genotyped. After exclusion in common with the discov-
ery stage (Nprevious history of cancers = 13, Nbenign breast disease = 4, Nmetastatic disease = 16, Nfollow-up time
of less than 90 days = 86), 1,616 subjects remained. The subjects with unknown tumor subtypes were
also excluded, and a total of 1,494 subjects were included in the replication set in this study.
All participants in this study provided written informed consent. The study design was ap-
proved by the Committee on Human Research of Seoul National University Hospital (IRB No.
H-0503-144-004).
Tumor Subtypes
Information on ER, PR, and HER2 status was obtained from the medical records of patients’
based on laboratory results and the interpretation of pathologists. The ER and PR status was
determined with immunohistochemistry (IHC) test. When ER and/or PR tumor cells showed
10% or more expression by IHC, the hormone receptor (HR) status was considered positive.
Otherwise, HR was considered negative when both ER and PR tumor cells showed less than
10% expression by IHC. The HER2 status was defined by IHC and fluorescence in situ hybrid-
ization (FISH) tests according to HercepTest criteria[31]. When using the IHC staining score
of HER2, 0 or 1+ was regarded as negative, while 3+ was considered as positive. When the IHC
staining score of HER2 was 2+, the HER2 status was estimated with the FISH test. Tumor sub-
types were classified as ER and/or PR positive and HER2 negative (HR+ HER2-), ER and/or
PR positive and HER2 positive (HR+ HER2+), ER and PR negative and HER2 positive (HR-
HER2+), and ER and PR negative and HER2 negative (HR- HER2-) subtypes.
Genotyping and Quality Control
Genotyping was conducted using Affymetrix Genome-Wide Human SNP array 6.0 chip (Affy-
metrix, Inc.) and quality control steps ((a) a p-value<1.0×10-6 for deviation from Hardy-
Weinberg equilibrium (HWE), (b) a call rate<95%, (c) a minor allele frequency (MAF)<1%,
(d) a p-value<1.0×10-4 for differential missingness between cases and controls, and (e) multiple
positioning and/or mitochondrial SNPs) were considered, as previously described[29]. Finally, a
total of 555,525 genotyped SNPs remained in the discovery set. Moreover, an imputation of the
SNPs based on the Han Chinese from Beijing and Japanese from Tokyo (CHB+JPT) data from
the HapMap Phase II database (release 22) as a reference panel was done with the hidden Mar-
kov model using MaCH 1.0[32]. Among the 2,416,663 inferred SNPs, 2,210,580 remained after
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excluding SNPs that had an imputation quality score (r2) of<0.3 in the discovery set. When
SNPs were genotyped as well as imputed, the information from the genotyped SNPs was used.
For the replication set, SNPs with a p-value less than 5.0×10-6 and a MAF equal to or more
than 10% for the per allele hazard ratio (HR) were selected from each tumor subtype in the dis-
covery stage. A total of 10 lead SNPs that included other SNPs in linkage disequilibrium (LD,
r2>0.4) at loci with multiple SNPs were selected for genotyping in the replication stage as fol-
lows: rs161041, rs2835688, rs9935088, and rs166870 in HR+ HER2-; rs1896346 and
rs12940572 in HR+ HER2+; rs34073156 and rs10906761 in HR- HER2+, and rs10825036 and
rs10862597 in HR- HER2-. Proxy SNPs, rs1081228 (r2 = 0.98) and rs4750561 (r2 = 1.00), were
genotyped for rs166870 at 15q25 and rs10906761 at 10p31, respectively, because of the geno-
typing failure of the original ones. The LD metrics (r2) of the selected SNP pairs were calculated
using the SNP Annotation and Proxy Search (SNAP) based on HapMap release 22 in the CHB-
+JPT population panel. When the selected SNP pairs showed LD (r2>0.4), SNPs with the low-
est p-value were selected for the per-allele HR, which were genotyped with the Fluidigm 192.24
Dynamic Array. Integrated Fluidic Circuit (IFC) (Fluidigm Corp. South San Francisco, CA,
USA) was used according to the manufacturer’s instructions. When the selected SNPs failed
genotyping, proxy SNPs were selected based on the LD metrics (r2) and genotyped. The success
rates for genotyping were greater than 99% for all replication SNPs.
Outcomes
The information on follow-up time, and recurrence status was obtained through retrospective-
ly reviewing the patients’ medical records. The DFS time was defined as the time from the
initial breast cancer surgery to the time of recurrence which includes loco-regional recurrence,
first distant metastasis, contralateral breast cancer, and second primary cancer. The breast
cancer patients who did not have evidence on recurrence were censored at last follow-up until
2011.
Statistical Analysis
The associations between each SNP and DFS stratified by tumor subtypes were estimated with
Cox proportional hazard models adjusted for age, recruiting center, and TNM stage. The haz-
ard ratios (HRs) and 95% confidence intervals (CIs) per allele for each SNP were assessed in
the additive model which was based on the number of rare alleles carried. The statistical signifi-
cance of the associations was estimated with the p-value for the trend test with 1 degree of free-
dom. The analyses were done with the PLINK program version 1.07 and R 2.15.1 package
(GenABEL and ProbABEL) and confirmed with SAS 9.3. To validate previously reported asso-
ciation, the SNPs identified from previous GWAS also analyzed. Using web-based Locus
Zoom, regional association plots of the selected gene regions were generated. To estimate com-
bined associations of the discovery and replication sets between SNPs and DFS, random-effects
meta-analyses were done with STATA version 12.
A recursive partitioning analysis (RPA) of the prognostic factors was performed to classify
breast cancer patients by distinguished groups based on the survival time[33]. The prognostic
factors assessed by RPA were age, recruiting center, TNM stage, tumor subtype, and selected
SNPs (rs166870 and rs10825036) were included. RPA was also done within specific tumor sub-
types for those SNPs from the GWAS that were considered predictive factors. Kaplan-Meier
graphs and HRs and 95% CIs of the Cox model are presented for the combined prognostic
groups. Within each group, the probabilities of DFS and the percentage of breast cancer pa-
tients were measured. The predictive powers of survival models which included age, recruiting
centers, TNM stage, and tumor subtypes with or without selected SNPs were calculated with
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Harrell’s C statistics, and the differences between the predictive powers were estimated with
the p-value expressed by the lincom command in STATA. All statistical analyses were done
again among patients with TNM stage I-III as a sensitivity analysis, and a statistically signifi-
cant level was a two-sided p-value of 0.05.
Results
Characteristics of the Study Population
The characteristics of the 3,226 study participants and the associations with DFS are summa-
rized in Table 1. The median follow-up time was 3.8 years (range, 0.3–8.0 years) in the discov-
ery and 4.6 years (range, 0.3–8.5 years) in the replication sets. During the follow-up period, 214
(12.4%) patients in the discovery set and 164 (11.0%) patients in the replication set had events.
Tumor size, nodal status, TNM stage, and tumor subtypes were statistically significant in asso-
ciations with DFS in both the discovery and replication sets. The participants had a similar dis-
tribution for age, nodal status and ER and PR status, but a different distribution for tumor size,
TNM stage, HER2 status, and breast tumor subtypes between discovery and replication sets (p-
value<0.05 by Chi-square test). The characteristics including age, TNM stage, and tumor sub-
types were not significantly different between remained and excluded subjects due to follow-up
loss (data not shown). The characteristics of the study participants by tumor subtypes are pre-
sented in S1 Table.
Genome-Wide Association Study on Prognosis
The associations between previously identified SNPs through the GWAS of prognosis and DFS
in the SEBCS by tumor subtypes are listed in S2 Table. Although none of those SNPs reported
in the previous GWAS were further replicated in the overall breast cancer, 4 SNPs showed sig-
nificant associations with DFS in the specific tumor subtypes.
Although there were no SNPs that reached a nominal genome-wide statistical significance
(p-value<5.0×10-8), a total of 10 SNP for DFS achieved p-values of 5.0×10-5f in each subtype
in the discovery set (Table 2). Among these SNPs, rs166870 in HR+ HER2- (ptrend = 0.03)
and rs10825036 in HR- HER2- (ptrend = 0.06) had statistically marginal significance in the
replication set (Table 2). The regional plots for those two SNPs in associations with DFS in
breast cancer for each subtype are shown in Fig 1. In combined analyses of the discovery and
replication sets, those two SNPs had strong associations among breast cancer patients for
each subtype (HRrs166870 = 2.30, 95% CI = 1.67–3.15, ptrend = 2.88×10
-7 in HR+ HER2- and
HRrs10825036 = 2.26, 95% CI = 1.34–3.81, ptrend = 3.54×10
-7 in HR- HER2-, Table 2). The re-
sults were similar when breast cancer patients with TNM stage 0 were excluded (S3 Table).
To identify the heterogeneity of the prognosis for those SNPs according to tumor subtypes,
the associations with DFS for the other tumor subtypes of breast cancer were estimated, and
they were not statistically associated with the other subtypes (Fig 2) and p-values for hetero-
geneity by tumor subtypes were statistically significant (prs166870<0.01 and prs10825036 = 0.02
in combined set).
Prognostic Value of the Combined Markers of Clinical and Genetic
Factors
RPA classified patients into distinct prognostic groups in each subtype shown in Table 3, which
were significantly associated with the DFS of breast cancer in both the discovery and replication
sets. The rs166870 (CC+CT or TT) was the second node among the HR+ HER2- patients after
the TNM stage (0-II or III) (pdiscovery = 1.18×10
-8 and preplication = 2.08×10–5, Table 2), and
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Table 1. Characteristics of breast cancer patients and associations with disease-free survival (DFS).
Discovery set Replication set
Ntotal (%) Nevent (%) HR
a (95% CI) Ntotal (%) Nevent (%) HR
a (95% CI)
No. of patients 1,732 (100.0) 214 (100.0) 1,494 (100.0) 164 (100.0)
Median follow-up time, years
(range)
3.8 (0.3–
8.0)
2.1 (0.3–
8.1)
4.6 (0.3–
8.5)
2.2 (0.3–
8.0)
Total time at risk, person-years 6978.4 562.0 6677.8 429.4
Median age at surgery, years
(range)
47 (26–82) 46 (30–82) 1.01 (0.99–
1.02)
47 (21–82) 44 (21–74) 0.98 (0.97–
1.00)
Tumor size
2 cm 942 (54.4) 69 (32.2) 1.00 ref. 798 (53.4) 54 (32.9) 1.00 ref.
2–5 cm 648 (37.4) 109 (50.9) 1.58 (1.15–
2.18)
638 (42.7) 94 (57.3) 1.63 (1.15–
2.32)
>5 cm 98 (5.7) 33 (15.4) 2.95 (1.87–
4.64)
51 (3.4) 16 (9.8) 3.25 (1.79–
5.87)
Nodal status
negative 1,059 (61.1) 80 (37.4) 1.00 ref. 933 (62.5) 68 (41.5) 1.00 ref.
positive 673 (38.9) 134 (62.6) 2.15 (1.59–
2.91)
561 (37.6) 96 (58.5) 2.19 (1.57–
3.06)
TNM stage
0 167 (9.6) 5 (2.3) 0.44 (0.18–
1.12)
29 (1.9) 0 (0.0) -
I 596 (34.4) 43 (20.1) 1.00 ref. 566 (37.9) 35 (21.3) 1.00 ref.
II 694 (40.1) 87 (40.7) 1.51 (1.04–
2.18)
705 (47.2) 82 (50.0) 1.85 (1.24–
2.75)
III 275 (15.9) 79 (36.9) 4.15 (2.84–
6.06)
194 (13.0) 47 (28.7) 4.63 (2.97–
7.22)
ER status
positive 1,069 (61.7) 100 (46.7) 1.00 ref. 921 (61.7) 81 (49.4) 1.00 ref.
negative 663 (38.3) 114 (53.3) 1.53 (0.13–
2.08)
573 (38.4) 83 (50.6) 1.35 (0.96–
1.89)
PR status
positive 936 (54.0) 76 (35.5) 1.00 ref. 778 (52.1) 63 (38.4) 1.00 ref.
negative 793 (45.8) 138 (64.5) 1.75 (1.28–
2.39)
714 (47.8) 101 (61.6) 1.33 (0.94–
1.89)
HER2 status
negative 1,270 (73.3) 152 (71.0) 1.00 ref. 1,186 (79.4) 107 (65.2) 1.00 ref.
positive 462 (26.7) 62 (29.0) 0.90 (0.66–
1.23)
308 (20.6) 57 (34.8) 1.60 (1.15–
2.24)
Tumor subtypes
HR+ HER2- 995 (57.5) 91 (42.5) 1.00 ref. 907 (60.7) 68 (41.5) 1.00 ref.
HR+ HER2+ 241 (13.9) 26 (12.2) 1.11 (0.72–
1.73)
162 (10.8) 28 (17.1) 1.87 (1.20–
2.93)
HR- HER2+ 221 (12.8) 36 (16.8) 1.93 (1.30–
2.86)
146 (9.8) 29 (17.7) 2.51 (1.61–
3.90)
HR- HER2- 275 (15.9) 61 (28.5) 2.41 (1.73–
3.35)
279 (18.7) 39 (23.8) 1.76 (1.18–
2.62)
Abbreviations: DFS, disease-free survival; HR, hazard ratio; CI, conﬁdence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human
epidermal growth factor receptor 2; HR, hormone receptor; ref. reference.
aCox proportional hazard model adjusted for age, recruiting center, TNM stage, and tumor subtypes.
doi:10.1371/journal.pone.0122413.t001
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rs10825036 (TT+TG or GG) was the only node among the HR- HER2- patients showing signifi-
cant differences between the groups (pdiscovery = 2.35×10
-4 and prelication = 2.60×10
-2, Table 3).
The similar results were presented when breast cancer patients with TNM stage 0 were excluded
(S4 Table).
Fig 1. Regional plots for SNPs, (A) rs166870 and (B) rs10825036, in associations with DFS in the HR+ HER2- and HR- HER2- breast cancer subtype,
respectively.
doi:10.1371/journal.pone.0122413.g001
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The predictive powers of DFS for breast cancer were compared between the model with
clinical variables alone and the model with combined clinical and genetic variables, and the lat-
ter tended to have better predictive powers in overall (Harrell’s Cclinical model = 70.92% and Har-
rell’s Ccombined model = 71.37%, p = 0.03), HR+ HER2- (Harrell’s Cclinical model = 65.08% and
Harrell’s Ccombined model = 66.69%, p<0.01), and HR- HER2- breast cancer (Harrell’s Cclinical
model = 63.26% and Harrell’s Ccombined model = 65.88%, p<0.01).
Fig 2. Associations between selected SNPs and disease-free survival (DFS) of breast cancer patients by tumor subtypes. (A) rs166870. (B)
rs10825036.
doi:10.1371/journal.pone.0122413.g002
Table 3. Associations between different combined groups of clinical and genetic factors and disease-free survival (DFS) among breast cancer
patients.
Discovery set Replication set
HRa (95% CI) P HRa (95% CI) P
Group by RPA among HR+ HER2- breast cancer patients
Group 1: TNM stage 0-II and rs166870CC+CT 1.00 ref. 1.18×10
-8 1.00 ref. 2.08×10-5
Group 2: TNM stage 0-II and rs166870TT 5.52 (2.00–15.28) 2.01 (0.90–4.47)
Group 3: TNM stage III and rs166870CC+CT 3.61 (2.29–5.68) 3.07 (0.64–14.83)
Group 4: TNM stage III and rs166870TT 10.50 (1.43–77.06) 7.26 (2.95–17.88)
Group by RPA among HR- HER2- breast cancer patients
Group1: rs10825036TT+TG 1.00 ref. 2.35×10
-4 1.00 ref. 2.60×10-2
Group2: rs10825036GG 3.45 (1.78–6.67) 2.17 (1.10–4.28)
Abbreviations: DFS, disease-free survival; HR, hazard ratio; CI, conﬁdence interval; RPA, recursive partitioning analysis; HR, hormone receptor; HER2,
human epidermal growth factor receptor 2.
aCox proportional hazard model adjusted for age and recruiting center, additional TNM stage for group by tumor subtypes and selected SNPs.
doi:10.1371/journal.pone.0122413.t003
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Discussion
From the two-stage GWAS, genetic factors that were associated with DFS in breast cancer were
identified by tumor subtypes, and the prognostic values for the combined clinical and genetic
factors were evaluated. The SNPs, rs166870 and rs10825036, showed a statistically significant
association with DFS in the HR+ HER2- and HR- HER2-breast tumor subtypes, respectively,
and these associations were not seen in the other tumor subtypes. They contributed to the
prognostic models by improving the prediction of DFS within specific subtypes.
We conducted a subtype-specific GWAS, unlike other previous studies that had conducted
a GWAS for overall breast cancer before stratifying by ER, PR, and HER2 status because breast
cancer is considered as a heterogeneous disease for which the prognosis varies across subtypes
[34]. This intertumor heterogeneity is plausible in that breast cancer could originate from dif-
ferent cell types according to the tumor subtype[35] and is supported by previous studies show-
ing the heterogeneous associations between SNPs and the prognosis of breast cancer by ER, PR
and HER2 status[15,18–27], in agreement with the current study (Fig 2). Another reason for
the subtype-specific analyses was that breast cancer subtypes are considered as a predictor fac-
tor that distinguishes different responses to particular therapies among patients[36]. Because
those differences in responses to particular therapies could have been a result of subtype-specif-
ic biological differences, the stratification of breast tumors by subtypes is necessary[37].
Among previously identified SNPs by GWAS for the prognosis of breast cancer, none of the
SNPs were associated with DFS overall in this study (S2 Table). Of those SNPs that showed an
association in the subtypes, rs3784099 and rs9934948 had been associated with the total mor-
tality, for overall and ER+ breast cancer in Chinese women[15]. Although the association of
SNP rs9934948 was not in the same direction as in this study, the reason for this might be be-
cause the tumor subtypes, specifically HR+ and HR-, had a different tumor biology from that
of ErbB2, and the luminal subtypes showed entirely different up-regulated gene patterns even
in the same organ relapse patients[38]. The other identified SNPs, rs1387389, rs2774307, and
rs4778137 (especially in ER-), are associated with survival in European women, and the same
directions for the estimates are shown in our patients[12,14]. The SNP rs4778137 is also signif-
icantly associated with the overall survival (OS) of breast cancer in Chinese women, even
though it has not been replicated in the ER- subtype[15].
In the region surrounding the SNP rs166870, an acetylation of lysine 27 as an activation
mark in the H3 histone protein (H3K27Ac) was observed by in silico analysis (S1A Fig).
Rs166870 is close to the methenyltetrahydrofolate synthetase (MTHFS) gene, which is involved
in folate mediated one-carbon metabolism. Although associations between SNPs in theMTHFS
gene and the risk and prognosis of breast cancer have not been reported, an association has
been reported betweenMTHFS variants and the prognosis of lung cancer[39], and also other
one-carbon metabolism pathway genes are associated with the prognosis of breast cancer
[22,40–42]. One-carbon metabolism influences DNAmethylation and synthesis[43], regulating
Bcl-2/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3). The loss of BNIP3 expression has
been correlated with poor prognostic features such as lymph node metastasis, a higher mitotic
activity index (MAI), and tubule formation in breast cancer[44]. Moreover, the MTHFS protein
is known as a potential mediator of insulin-like growth factor-1 receptor (IGF-1R) dependent
transformation[45]. Breast cancer patients, especially HR+, HER2-, and tumor patients with a
Ki-6714%, who had a better score for IGF-1R expression had a higher survival[46].
SNP rs10825036 was also represented as a H3K27Ac mark by in silico analysis (S1B Fig). Al-
though there are no studies on rs10825036, the SNP was weakly correlated with rs583012,
which was associated with the c-reactive protein[47], and rs12256830 was associated with anti-
body levels[48]. Rs10825036 is close to the PCDH15 gene which encodes integral membrane
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proteins that mediate calcium-dependent cell-cell adhesion. Previously, the SNPs of the
PCDH15 gene are known for associations with adverse events caused by chemotherapy in
breast cancer[49] as well as with lipid abnormalities[50]. The lipid profiles have been associated
with the risk, stage, and recurrence of breast cancer[51–53]. Moreover, lipids profiles have
been distinguished between triple-negative and other breast tumor subtypes[54].
The predictive power of the combined model including rs166870 and rs10825036 identified
from the two-stage GWAS, was more improved than that of the clinical model which did not
include the SNPs. In previous multivariate survival models, Harrell’s C statistics were estimated
ranging from 0.69 to 0.82 according to the number and type of clinicopathological factors and
the characteristics of the study population included in the models[55–57]. There were no SNPs
whose c-indices were estimated, but the gene expression signatures improved the predictive
powers when additionally included in multivariate clinicopathological models[58].
To assign the risk group according to the prognosis of breast cancer, clinical and genetic fac-
tors were combined and re-classified with RPA. From the results of the RPA, the genetic factors
selected from the two-stage GWAS were more valuable when the analyses were stratified by
tumor subtypes, and only one node of the genetic factors was statistically significant regardless
of the clinical factors in HR- HER2- breast cancer. Therefore, prognostic markers that include
the SNPs identified from the GWAS could be valuable in predicting the prognosis of breast
cancer, particularly in specific tumor subtypes.
This is the first study that conducted a two-stage GWAS by tumor subtypes based on HR
and HER2 status. Furthermore, combined survival models that include genetic factors identi-
fied by the two-stage GWAS as well as other well-known clinical factors were evaluated for pre-
dicting the prognosis of breast cancer. The first limitation of this study was that the statistical
significances of the associations from the two-stage GWAS did not reach a p-value<5.0×10-8
as the nominal significance for the GWAS[59]. However, there have been a few GWAS on the
prognosis of breast cancer, and none of the SNPs associated with the prognosis of breast cancer
have had a nominal significance from the GWAS so far[11–15]. Second, the treatment infor-
mation for breast cancer was not controlled in the analyses because of substantial missing data.
Although the adjuvant chemotherapy and radiation did not affect associations of survival, the
hormone therapy was associated with survival in the discovery set but not in the replication set
(data not shown), which tended to depend on the tumor subtypes. All the analyses were adjust-
ed or stratified by tumor subtypes instead of controlling for treatments.
It has been inconclusive whether genetic factors influence survival by intrinsic subtypes.
In this analysis, the novel genetic markers including rs166870 and rs10825036 were associat-
ed with survival in HR+ HER2- and HR- HER2- tumors showing heterogeneity between
tumor subtypes. The novel genetic markers identified in this study would be helpful to under-
stand biological insights in heterogeneous breast cancer patients. Furthermore, RPA showed
those genetic markers played a role in distinguishing between high and low risk groups of
breast cancer patients. The combined prognostic markers that include the genetic markers
and well-known clinical factors could be useful to predict the clinical outcome for breast
cancer patients.
In conclusion, our two-stage GWAS identified two novel SNPs (rs166870 and rs10825036)
associated with DFS in the HR+ HER2- and HR- HER2- subtypes, respectively. When these ge-
netic factors were added to well-known clinical survival models that included age, TNM stage,
and tumor subtype, improved predictive powers of the models were observed. Furthermore,
our RPA showed that genetic factors had a role in distinguishing between high and low risk
groups when using combined prognostic markers. To validate these results, further studies are
needed to evaluate the predictive power of the survival models which include genetic factors as
well as clinical factors.
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